摘要
Nitrosamine impurities have become a major pharmaceutical quality and patient-safety concern because several members of this chemical class possess mutagenic and carcinogenic potential. The modern pharmaceutical concern was highlighted by the detection of N-nitrosodimethylamine (NDMA) in valsartan products in 2018 and subsequently by findings involving other medicines and nitrosamine drug substance-related impurities (NDSRIs). This review summarizes the chemistry and classification of nitrosamines, their principal formation pathways and sources across the pharmaceutical lifecycle, toxicological mechanisms, analytical approaches, risk assessment, acceptable-intake concepts, regulatory management, and mitigation strategies. Nitrosamine formation generally involves a susceptible amine and a nitrosating environment, with pH, nitrite availability, temperature, moisture, reaction time, formulation composition, degradation and packaging influencing risk. Because many nitrosamines require metabolic activation and can generate DNA-reactive intermediates, exposure must be controlled at very low levels. Trace-level determination commonly uses GC-MS/MS, LC-MS/MS and high-resolution mass spectrometry, while reliable testing also depends on suitable sample preparation, artefact control and method validation. Modern management therefore emphasizes science-based risk assessment, root-cause prevention, structure-informed toxicological assessment, confirmatory testing and continuous lifecycle control. Future directions include predictive chemistry, AI-assisted risk assessment, non-targeted high-resolution screening, Process Analytical Technology and greener analytical workflows. Keywords: Nitrosamine impurities; NDMA; NDEA; NDSRIs; mutagenicity; carcinogenicity; LC-MS/MS; GC-MS/MS; risk assessment; acceptable intake